Pages that link to "Q67524559"
Jump to navigation
Jump to search
The following pages link to Smoking and schizophrenia (Q67524559):
Displaying 50 items.
- Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia (Q21562668) (← links)
- Neuropsychiatric effects of caffeine (Q22241711) (← links)
- A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors (Q22251463) (← links)
- Genetics of schizophrenia and smoking: an approach to studying their comorbidity based on epidemiological findings (Q24289498) (← links)
- Cigarettes and suicide: a prospective study of 50,000 men (Q24544041) (← links)
- Neuronal nicotinic receptors in the human brain (Q28141480) (← links)
- Schizophrenia and tobacco smoking: a replication study in another US psychiatric hospital (Q28207300) (← links)
- Human neuronal nicotinic receptors (Q29397943) (← links)
- nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives. (Q30362464) (← links)
- Effects of intravenous nicotine on prepulse inhibition in smokers and non-smokers: relationship with familial smoking (Q30432102) (← links)
- Patterns of deficits in brain function in bipolar disorder and schizophrenia: a cluster analytic study (Q30445337) (← links)
- Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia (Q30459624) (← links)
- Smoking, Genetics and Schizophrenia: Evidence for Self Medication (Q30491841) (← links)
- Cholinergic systems are essential for late-stage maturation and refinement of motor cortical circuits (Q30624044) (← links)
- Nicotinic modulation of neuronal networks: from receptors to cognition (Q30993631) (← links)
- Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view (Q33350202) (← links)
- Nicotine consumption and schizotypy in first-degree relatives of individuals with schizophrenia and non-psychiatric controls (Q33644537) (← links)
- Addiction and schizophrenia (Q33958615) (← links)
- Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder (Q33964656) (← links)
- Role of alpha7 nicotinic receptors in nicotine dependence and implications for psychiatric illness (Q34002770) (← links)
- Nicotinic receptors in human brain: topography and pathology (Q34156143) (← links)
- The association between schizophrenia and cigarette smoking: a review of the literature and implications for mental health nursing practice (Q34227972) (← links)
- Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia (Q34259921) (← links)
- Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications (Q34313506) (← links)
- Cholinergic systems and schizophrenia: primary pathology or epiphenomena? (Q34318020) (← links)
- Substance misuse in patients with schizophrenia: epidemiology and management (Q34585142) (← links)
- Smoking in schizophrenia -- all is not biological (Q34707915) (← links)
- Investigation of cigarette smoking among male schizophrenia patients (Q34970938) (← links)
- The potential role of cotinine in the cognitive and neuroprotective actions of nicotine (Q35111446) (← links)
- Cholinergic nicotinic receptors: Competitive ligands, allosteric modulators, and their potential applications (Q35112780) (← links)
- Schizophrenia, cancer and obstetric complications in an evolutionary perspective-an empirically based hypothesis (Q35144224) (← links)
- Pharmacogenetics as a tool in the therapy of schizophrenia (Q36110841) (← links)
- Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission (Q36633620) (← links)
- Extended use of nicotine replacement therapy to maintain smoking cessation in persons with schizophrenia (Q36713443) (← links)
- Incidence of cancer in patients with schizophrenia and their first-degree relatives: a population-based study in Sweden (Q36770024) (← links)
- Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking (Q36828536) (← links)
- Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study (Q37039179) (← links)
- Smoking topography and outcome expectancies among individuals with schizotypy. (Q37141290) (← links)
- Patient Safety Events and Harms During Medical and Surgical Hospitalizations for Persons With Serious Mental Illness (Q37307741) (← links)
- MBD-seq as a cost-effective approach for methylome-wide association studies: demonstration in 1500 case--control samples (Q37581443) (← links)
- Investigating causality in associations between smoking initiation and schizophrenia using Mendelian randomization (Q37593341) (← links)
- Prevalence of Substance Use in Patients Diagnosed with Schizophrenia (Q37704084) (← links)
- Antipsychotic medication and tobacco use among outpatients with schizophrenia: a cross-sectional study (Q37716277) (← links)
- Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. (Q37725116) (← links)
- A Reasonable Alternative to Clozapine in the Chronically Relapsing Smoking Patient? A Retrospective Analysis (Q39121457) (← links)
- A Randomized Controlled Trial of Ethyl Glucuronide-Based Contingency Management for Outpatients With Co-Occurring Alcohol Use Disorders and Serious Mental Illness (Q40358979) (← links)
- Personality, psychopathology, and nicotine response as mediators of the genetics of smoking (Q40515559) (← links)
- Environmental factors and membrane polyunsaturated fatty acids in schizophrenia (Q40548904) (← links)
- Adverse pregnancy outcome in schizophrenic women: occurrence and risk factors (Q40838877) (← links)
- Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature (Q41261022) (← links)